CDK4 and breast cancer: Of interest, upregulation of glutaminolysis as an adaptive mechanism is not limited as a survival response to CDK4/6i’s, having also been observed in response to other chemotherapeutic pressures, such as PARP inhibitors in breast cancer cells [94].